Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Federal Trade Commission
AstraZeneca
Boehringer Ingelheim
Moodys
Deloitte
Dow
Cipla
Julphar

Generated: December 10, 2018

DrugPatentWatch Database Preview

OLUMIANT Drug Profile

« Back to Dashboard

When do Olumiant patents expire, and when can generic versions of Olumiant launch?

Olumiant is a drug marketed by Eli Lilly And Co and is included in one NDA. There are two patents protecting this drug.

This drug has fifty patent family members in thirty-nine countries.

The generic ingredient in OLUMIANT is baricitinib. One supplier is listed for this compound. Additional details are available on the baricitinib profile page.

Summary for OLUMIANT
Drug patent expirations by year for OLUMIANT
Generic Entry Opportunity Date for OLUMIANT
Generic Entry Date for OLUMIANT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for OLUMIANT
(1-(Ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)ethanenitrile
1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile
1187594-09-7
1231199-29-3
1374987-77-5
2-(3-(4-(3H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile
2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile
2-[1-ETHYLSULFONYL-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PYRAZOL-1-YL]AZETIDIN-3-YL]ACETONITRILE
3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-
3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]-
3JW
AB0035958
ABP001023
AC-27404
AJ-121247
AKOS022186127
AKOS025401933
AM81232
AMMD00005
AOB87724
AX8261519
Baricitinib
Baricitinib (INCB28050 LY3009104)
Baricitinib (JAN/USAN/INN)
Baricitinib (LY3009104, INCB028050)
Baricitinib (LY3009104)
Baricitinib [USAN:INN]
BC600315
BCP0726000031
BCP9000380
BDBM50021656
C16H17N7O2S
CHEBI:95341
CHEMBL2105759
CS-0724
D0Y7IC
D10308
DB11817
DS-7641
DTXSID30152228
EX-A413
GTPL7792
HMS3651L17
HY-15315
IN2285
INCB 028050
INCB 28050
INCB-028050
INCB-028050|||LY-3009104|||2-[1-Ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
INCB-28050
INCB028050
INCB424-ANALOGUE
ISP4442I3Y
J-503551
KB-74852
KS-0000044L
LY 3009104
LY-3009104
LY3009104
MLS006011247
MolPort-023-219-125
NCGC00345839-01
Olumiant (TN)
PB27275
QCR-197
RL00725
S-7686
s2851
SC-94301
SCHEMBL871150
SMR004703006
UNII-ISP4442I3Y
XUZMWHLSFXCVMG-UHFFFAOYSA-N
Y0439
ZINC73069247

US Patents and Regulatory Information for OLUMIANT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly And Co OLUMIANT baricitinib TABLET;ORAL 207924-001 May 31, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Eli Lilly And Co OLUMIANT baricitinib TABLET;ORAL 207924-001 May 31, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Eli Lilly And Co OLUMIANT baricitinib TABLET;ORAL 207924-001 May 31, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for OLUMIANT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0170022 00232 Estonia ➤ Sign Up PRODUCT NAME: BARITSITINIIB;REG NO/DATE: EU/1/16/1170 15.02.2017
2017 00032 Denmark ➤ Sign Up PRODUCT NAME: BARICITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1 /16/1170 20170215
2017 00032 Denmark ➤ Sign Up PRODUCT NAME: BARICITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1 /16/1170 20170215
2017000045 Germany ➤ Sign Up PRODUCT NAME: BARICITINIB; REGISTRATION NO/DATE: EU/1/16/1170 20170213
90035-8 Sweden ➤ Sign Up PRODUCT NAME: BARICITINIB; REG. NO/DATE: EU/1/16/1170 20170215
2017023 Lithuania ➤ Sign Up PRODUCT NAME: BARICITINIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/16/1170 20170213
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
US Army
Argus Health
Harvard Business School
Moodys
QuintilesIMS
Cantor Fitzgerald
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.